- O
Outpace Bio
- Brad Hammerson
Brad Hammerson is a seasoned scientist with extensive experience in protein expression and purification, particularly in the context of infectious diseases, vaccine and drug development, and antibiotic resistance. Currently serving as a Scientist I at Outpace Bio since November 2020, Brad previously held roles at Seattle Children's Research Institute, including Senior Research Associate and Research Scientist II in the Myler Laboratory. Earlier positions include Research Associate roles at the Center for Infectious Disease Research and Prothena Corporation plc, as well as various research and quality control positions at companies such as Seattle Genetics and Genentech. Brad holds a Bachelor of Science degree in Microbiology from the University of California Santa Barbara.
Org chart
Teams
Offices
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.
